Skip to main content
OpenTrials

Clinical trial condition

Relapsing Multiple Sclerosis

Explore clinical trials studying Relapsing Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

68 public trials 10 recruiting studies
Refine in advanced search Browse all conditions

Relapsing Multiple Sclerosis trial results

Completed

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

NCT04410978

Conditions
Relapsing Multiple Sclerosis
Locations
  • University of Alabama MS Center-Site Number:8400013 Birmingham, Alabama, United States
  • University of San Francisco, Sandler Neurosciences Center-Site Number:8400137 San Francisco, California, United States
  • University of Colorado-Site Number:8400012 Aurora, Colorado, United States
  • Georgetown University Medical Center-Site Number:8400119 Washington D.C., District of Columbia, United States
View all 179 locations
View Trial Details
Completed

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

NCT04410991

Conditions
Relapsing Multiple Sclerosis
Locations
  • North Central Neurology Associates, PC-Site Number:8400009 Cullman, Alabama, United States
  • Center for Neurology and Spine-Site Number:8400089 Phoenix, Arizona, United States
  • Arcadia Neurology Center-Site Number:8400070 Arcadia, California, United States
  • Multiple Sclerosis Center of California-Site Number:8400135 Newport Beach, California, United States
View all 186 locations
View Trial Details
Completed

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

NCT04869358

Conditions
COVID-19, Coronaviridae Infections, Coronavirus Infections, +10 more
Locations
  • Novartis Investigative Site Berlin, Germany
  • Novartis Investigative Site Bielefeld, Germany
  • Novartis Investigative Site Dresden, Germany
  • Novartis Investigative Site Erbach im Odenwald, Germany
View Trial Details
Completed

Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

NCT04121403

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Department of Neurology - Drammen, Vestre Viken HF Drammen, Buskerud, Norway
  • Department of Neurology - Lillehammer, SI Lillehammer Lillehammer, Oppland, Norway
  • Department of Neurology, Stavanger universitetssykehus Stavanger, Rogaland, Norway
  • Department of Neurology - Førde, Helse Førde HF Førde, Sogn Og Fjordane, Norway
View Trial Details
Completed

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Hope Research Institute Center Neurology and Spine Phoenix, Arizona, United States
  • Infinity Clinical Research LLC Hollywood, Florida, United States
  • The MS Center for Innovation in Care St Louis, Missouri, United States
View Trial Details
Completed

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243

Conditions
Advancing Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +6 more
Locations
  • Novartis Investigative Site Birmingham, Alabama, United States
  • Novartis Investigative Site Cullman, Alabama, United States
  • Alabama Neurology Associates Homewood, Alabama, United States
  • Novartis Investigative Site Tucson, Arizona, United States
View all 55 locations
View Trial Details
Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

NCT01412333

Conditions
Relapsing Multiple Sclerosis
Locations
  • Hope Research Institute Phoenix, Arizona, United States
  • HonorHealth Neurology Scottsdale, Arizona, United States
  • Territory Neurology and Research Institute Tucson, Arizona, United States
  • Collaborative Neuroscience Research, LLC Long Beach, California, United States
View all 165 locations
View Trial Details
Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

NCT01247324

Conditions
Relapsing Multiple Sclerosis
Locations
  • 21st Century Neurology Phoenix, Arizona, United States
  • Mercy Medical Group Carmichael, California, United States
  • Scripps Clinic La Jolla, California, United States
  • MS Center of California Laguna Hills, California, United States
View all 142 locations
View Trial Details

Related conditions